

Product datasheet for TR304378

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

GCNT2 Human shRNA Plasmid Kit (Locus ID 2651)

Product data:

Product Type: shRNA Plasmids

Product Name: GCNT2 Human shRNA Plasmid Kit (Locus ID 2651)

Locus ID: 2651

Synonyms: bA360019.2; bA421M1.1; CCAT; CTRCT13; GCNT2C; GCNT5; IGNT; II; NACGT1; NAGCT1; ULG3

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection: Format:

Retroviral plasmids

Components: GCNT2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

2651). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 001491, NM 145649, NM 145655, NM 145649.3, NM 145649.4, NM 145655.2,

NM 145655.3, NM 001491.1, NM 001491.2, BC130524, BC074801, BC074802, NM 145649.5,

NM 001491.3, NM 145655.4

UniProt ID: Q06430

Summary: This gene encodes the enzyme responsible for formation of the blood group I antigen. The i

and I antigens are distinguished by linear and branched poly-N-acetyllactosaminoglycans,

respectively. The encoded protein is the I-branching enzyme, a beta-1,6-N-


acetylglucosaminyltransferase responsible for the conversion of fetal i antigen to adult I antigen in erythrocytes during embryonic development. Mutations in this gene have been associated with adult i blood group phenotype. Alternatively spliced transcript variants

encoding different isoforms have been described. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).